NAD+ Therapy: What the Research Looks At
Updated 2026-09-03
An education-first look at NAD+ therapy: what it is, how IV and precursor forms differ, and its regulatory status. Not medical advice.
What it is
NAD+, or nicotinamide adenine dinucleotide, is a coenzyme present in every living cell, involved in energy metabolism and cellular repair processes. It is technically not a peptide, unlike most other entries in this section, but it is frequently marketed and discussed alongside longevity peptides in wellness clinics and online communities, which is why this site groups it with that research cluster. NAD+ is offered in several forms: intravenous (IV) infusion, injectable formulations, and oral precursor supplements such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), which the body can convert toward NAD+ production. None of these forms has been approved by the FDA as a drug for a specific medical indication.
How it is studied
NAD+ metabolism has been studied extensively in basic cell biology research for decades, with a more recent wave of interest in its potential connection to aging and age-associated decline in cellular function. Human trials on NAD+ precursors like NR and NMN have grown in number in recent years, registered on ClinicalTrials.gov and searchable through PubMed, though most published human studies remain small and short in duration compared with the scale of trial needed to establish a definitive health outcome. IV NAD+ infusion, offered in many wellness and addiction-recovery clinics, has considerably less published controlled human trial data behind it than the oral precursor research, and much of what is publicly known about IV protocols comes from clinic marketing rather than peer-reviewed publication.
What the research looks at
Researchers have looked at NAD+ and its precursors in connection with cellular energy metabolism, DNA repair pathways, and markers associated with aging in cell and animal models, with a growing but still limited set of human studies examining precursor supplementation. These are described as active areas of investigation; a measured change in a blood biomarker following supplementation is not the same as a demonstrated change in a long-term health outcome, and researchers in this field are explicit that the two should not be conflated. IV-specific human research lags behind the oral precursor literature, which matters for anyone comparing the two delivery routes.
Regulatory status
Oral NAD+ precursor supplements such as NR and NMN have had a complicated regulatory
history in the United States, with FDA determinations on NMN's dietary supplement status
shifting more than once in recent years; readers should check the FDA's current stance
before assuming a fixed classification for either ingredient. IV and injectable NAD+
products are not approved drugs and fall under the general compounding framework that
applies to other unapproved substances discussed on this site (see
/regulation/fda-category-2-list-explained/ and
/regulation/503a-vs-503b-compounding-explained/). For the most current federal posture,
see /regulation/fda-compounding-rulings-2026-update/. International rules on NAD+
precursor supplements and IV clinic offerings vary by country; see the relevant
/regulation/ pages before assuming the same status applies elsewhere.
Safety signals reported
Oral NAD+ precursor supplements have a relatively established safety record at studied doses in the published human trials available, though long-term data remains limited. IV NAD+ infusion carries additional considerations specific to any infusion procedure, including infusion-site reactions and the general risks associated with an unapproved, compounded intravenous product administered outside a hospital pharmacy setting. Reported side effects from IV NAD+ in clinical and anecdotal accounts have included nausea and infusion-related discomfort during administration. Anyone with a chronic kidney or liver condition should discuss any NAD+-related product, oral or IV, with a provider before use. This is not medical advice. Discuss any decision about NAD+ supplementation or infusion with a licensed healthcare provider first.
Questions to ask a clinician
- Which specific NAD+-related product or precursor are we discussing, and what evidence exists for that specific form?
- What is the current regulatory status of this specific compound given how often it has changed?
- What would an IV infusion involve, and how does the clinic verify the product's sourcing and quality?
- Do I have a kidney, liver, or other condition that would make this relevant to discuss first?
- What outcome, specifically, would we be tracking to know whether this is worth continuing?
FAQ
Is NAD+ actually a peptide? No, technically NAD+ (nicotinamide adenine dinucleotide) is a coenzyme, not a peptide, though it is frequently discussed alongside longevity peptides in the same wellness and clinic settings, which is why this site covers it in that context.
Is IV NAD+ therapy approved by the FDA? No. NAD+ administered by IV infusion has not been approved by the FDA as a drug for any indication, and clinics offering it are providing a compounded or unapproved product rather than an approved therapy.
What is the difference between IV NAD+ and oral precursors like NR or NMN? IV NAD+ delivers the coenzyme directly into the bloodstream through a compounded infusion, while nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are oral precursor compounds the body can convert toward NAD+ production; they are studied and regulated differently and are not interchangeable in an evidence sense.
Is NAD+ decline linked to aging? Researchers have reported that measured NAD+ levels tend to decline with age in various tissues studied, and this observation has driven a substantial amount of research interest. That observation is distinct from a claim that restoring NAD+ levels changes the aging process itself, which remains an open research question.
Sources
- PubMed, search results for "NAD+ aging coenzyme" -- https://pubmed.ncbi.nlm.nih.gov/?term=NAD%2B+aging+coenzyme
- FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503B -- https://www.fda.gov/drugs/human-drug-compounding/fda-issues-list-bulk-drug-substances-outsourcing-facilities-may-use-compound-under-section-503b
- ClinicalTrials.gov, search results for "NAD+" -- https://clinicaltrials.gov/search?term=NAD%2B
Disclaimer
This content is for general education only and is not medical advice, diagnosis, or treatment. Peptide Briefs does not sell peptides and does not recommend any specific product, dose, or protocol. These statements have not been evaluated by the Food and Drug Administration. Always talk with a licensed healthcare provider before starting, stopping, or changing any therapy.